SCHEMBL6444478

SCHEMBL6444478

CSc1nc(N)nc(-n2cc(C)cn2)c1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.43
KMT2A Q03164 10/20 0.43
MAPT P10636 9/20 0.43
LMNA P02545 6/20 0.43
HSD17B10 Q99714 3/20 0.43
CASP1 P29466 2/20 0.43
CASP7 P55210 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
NPSR1 Q6W5P4 5/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP3A4 P08684 1/20 0.41
ALDH1A1 P00352 9/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 2/20 0.39
HPGD P15428 4/20 0.39
RXFP1 Q9HBX9 1/20 0.39
PKM P14618 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6440583 0.87 CYP1A2 (0.41) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6441931 0.86 RXFP1 (0.41) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6446101 0.86 ALDH1A1 (0.44) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6442525 0.77 ADORA2A (0.56) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6442324 0.77 TDO2 (0.34) TDO2
SCHEMBL6443544 0.76 CYP1A2 (0.44) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6445909 0.76 ALDH1A1 (0.38) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL967156 0.73 ALDH1A1 (0.59) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL6445444 0.72 KMT2A (0.47) MEN1KMT2AMAPTLMNAHSD17B10
SCHEMBL27573259 0.67 ADORA1 (0.67) MEN1KMT2AMAPTLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 MEN1 4860/4885KMT2A 2463/4885MAPT 1878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.